Bristol-Myers Squibb: 3 Key Takeaways for Long-Term Investors

Source The Motley Fool

Key Points

  • Growth portfolio revenue rose 12% year over year to $7.7 billion.

  • Eight growth portfolio medicines annualized over $1 billion each.

  • Full-year 2026 adjusted EPS guidance was $6.35 to $6.55.

  • Motley Fool Issues Rare "Total Conviction" Buy Alert ›

On its third-quarter 2026 earnings call, held on Oct. 29, 2026, Bristol-Myers Squibb (NYSE:BMY) announced an increase to its full-year earnings guidance as expanding sales across new medicines offset generic competition on older treatments. The drugmaker is building a broader commercial base to absorb upcoming loss of exclusivity (LOE), or patent expiration, on major therapies while advancing its drug development pipeline.

Management offers three takeaways on how the strategy is unfolding.

1. Eight Core Growth Medicines Now Exceed $1 Billion in Annualized Sales

The company expanded revenue in its growth portfolio by 12% year over year to $7.7 billion during the quarter. Diversifying revenue across multiple blockbuster drugs helps replace sales lost as older therapies face generic competition.

First, sustaining the momentum across our growth portfolio. We now have 8 growth portfolio medicines, each annualizing over $1 billion based on Q3 sales, giving us a broad base of growth drivers.
-- Christopher S. Boerner, Board Chair and Chief Executive Officer

2. Late-Stage Clinical Trials Are Delivering Clinical and Regulatory Wins

Management advanced four registrational late-stage clinical trials over two months across oncology and rare lung diseases. The accelerated Food and Drug Administration (FDA) clearance of Symvexis, an oral therapy for multiple myeloma, establishes a new revenue driver in blood cancer care.

The momentum in our late stage pipeline has accelerated. In the past 2 months alone, we announced positive data for 4 registrational studies.
-- Christopher S. Boerner, Board Chair and Chief Executive Officer

3. Spending Efficiencies Support Reinvestments and Shareholder Returns

A strategic productivity initiative is driving $2 billion in cost savings to protect operating margins as legacy drug sales decline. Management generated $4.2 billion in operating cash flow during the quarter while raising full-year adjusted earnings per share (EPS) guidance.

Our third quarter results reflect continued strong execution of our growth portfolio and continued strength from Eliquis. We remain focused on financial discipline, balancing investments in our growth drivers with continued productivity improvements.
-- David V. Elkins, Chief Financial Officer

Looking Ahead

Commercial execution is accelerating across new therapeutic launches, and management isn't hiding its satisfaction with the momentum. The company is leaning on proprietary manufacturing sites, pipeline execution, and cost discipline to secure future cash flows.

Taken together, we are entering the final quarter of the year with real momentum. Our growth portfolio is performing well, We are advancing our pipeline with meaningful wins and remain highly disciplined in ensuring our cost structure is aligned with our revenue base.
-- Christopher S. Boerner, Board Chair and Chief Executive Officer

The business faces an estimated $1.5 billion to $2 billion revenue step-down in 2027 from European patent expirations on blood thinner Eliquis. Even so, internal manufacturing investments and active drug development create a resilient platform for long-term shareholder value.

As we continue to execute, we are well positioned to deliver long term durable growth into the next decade.
-- Christopher S. Boerner, Board Chair and Chief Executive Officer

Should you buy stock in Bristol Myers Squibb right now?

Before you buy stock in Bristol Myers Squibb, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Bristol Myers Squibb wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $321,850!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $955,232!*

Now, it’s worth noting Stock Advisor’s total average return is 793% — a market-crushing outperformance compared to 203% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 18, 2026.

The Motley Fool has positions in and recommends Bristol Myers Squibb. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
US Dollar Index Price Forecast: DXY could target 104.00 as bulls await FOMC MinutesThe US Dollar Index (DXY), which tracks the Greenback against a basket of currencies, regains positive traction following the previous day's brief pause, retesting its highest level since April 2025 during the first half of the European session on Wednesday.
Author  FXStreet
10 hours ago
The US Dollar Index (DXY), which tracks the Greenback against a basket of currencies, regains positive traction following the previous day's brief pause, retesting its highest level since April 2025 during the first half of the European session on Wednesday.
placeholder
Gold Hits Near 1.5-Year Low Below $3,800 as Bears Threaten Drop to $3,500Gold prices broke below the $3,800 threshold to hit a new low since September 2025, warranting heightened vigilance over downside risk toward $3,500.On November 18, international spot gol
Author  TradingKey
12 hours ago
Gold prices broke below the $3,800 threshold to hit a new low since September 2025, warranting heightened vigilance over downside risk toward $3,500.On November 18, international spot gol
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 18, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 18, 2026. Read on for the details.
Author  Mitrade
17 hours ago
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 18, 2026. Read on for the details.
placeholder
Nvidia posts record $115.8B Q3 revenue, but crypto stays mutedThe crypto market remained subdued on Tuesday despite Nvidia's (NVDA) Q3 earnings release beating analysts' expectations as demand for artificial intelligence infrastructure continued to drive growth across its business.
Author  FXStreet
19 hours ago
The crypto market remained subdued on Tuesday despite Nvidia's (NVDA) Q3 earnings release beating analysts' expectations as demand for artificial intelligence infrastructure continued to drive growth across its business.
placeholder
Nvidia Q3 Earnings Loom as Market Expects Revenue Near $109 Billion: Can NVDA Stock Hold $150? As of the close on November 16 ET, Nvidia (NVDA) shares fell 4.12% to close at $156.14, with an intraday low of $155.01 and trading volume of about 334 million shares. Compared with its p
Author  TradingKey
Yesterday 09: 10
As of the close on November 16 ET, Nvidia (NVDA) shares fell 4.12% to close at $156.14, with an intraday low of $155.01 and trading volume of about 334 million shares. Compared with its p
goTop
quote